JPWO2020124032A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020124032A5 JPWO2020124032A5 JP2021533535A JP2021533535A JPWO2020124032A5 JP WO2020124032 A5 JPWO2020124032 A5 JP WO2020124032A5 JP 2021533535 A JP2021533535 A JP 2021533535A JP 2021533535 A JP2021533535 A JP 2021533535A JP WO2020124032 A5 JPWO2020124032 A5 JP WO2020124032A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- item
- agent
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024214382A JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779885P | 2018-12-14 | 2018-12-14 | |
| US62/779,885 | 2018-12-14 | ||
| US201962836520P | 2019-04-19 | 2019-04-19 | |
| US62/836,520 | 2019-04-19 | ||
| PCT/US2019/066376 WO2020124032A1 (en) | 2018-12-14 | 2019-12-13 | Transferrin receptor targeting peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214382A Division JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513798A JP2022513798A (ja) | 2022-02-09 |
| JP2022513798A5 JP2022513798A5 (https=) | 2022-12-20 |
| JPWO2020124032A5 true JPWO2020124032A5 (https=) | 2022-12-20 |
| JP7664158B2 JP7664158B2 (ja) | 2025-04-17 |
Family
ID=71077078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533535A Active JP7664158B2 (ja) | 2018-12-14 | 2019-12-13 | トランスフェリン受容体標的ペプチド |
| JP2024214382A Pending JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214382A Pending JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220048961A1 (https=) |
| EP (1) | EP3893913B1 (https=) |
| JP (2) | JP7664158B2 (https=) |
| CN (1) | CN113329758A (https=) |
| AU (1) | AU2019398467A1 (https=) |
| CA (1) | CA3120466A1 (https=) |
| IL (1) | IL283839A (https=) |
| WO (1) | WO2020124032A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| CN111647048B (zh) * | 2020-06-22 | 2021-04-02 | 中国科学院昆明动物研究所 | 干扰多肽在制备抗SARS-CoV-2药物中的应用 |
| US12076364B2 (en) | 2020-06-22 | 2024-09-03 | Kunming Institute Of Zoology, Chinese Academy Of Sciences | Use of interference peptide in preparation of anti-SARS-CoV-2 medicament |
| JP2022014707A (ja) * | 2020-07-07 | 2022-01-20 | 東亞合成株式会社 | キャリアペプチドフラグメントおよびその利用 |
| CN116075524A (zh) * | 2020-07-30 | 2023-05-05 | 华盛顿大学 | 转铁蛋白受体结合蛋白 |
| AU2021386254A1 (en) * | 2020-11-30 | 2023-06-29 | Blaze Bioscience, Inc. | Compositions and methods for selective depletion of target molecules |
| WO2022180628A1 (en) * | 2021-02-23 | 2022-09-01 | Ichilov Tech Ltd. | Fusion proteins for treating cns diseases |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023023031A2 (en) * | 2021-08-17 | 2023-02-23 | Blaze Bioscience, Inc. | Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof |
| JPWO2023022234A1 (https=) * | 2021-08-19 | 2023-02-23 | ||
| CN118556069A (zh) * | 2021-10-01 | 2024-08-27 | 首尔大学校产学协力团 | 用于穿透血脑屏障的肽及其用途 |
| CN118139896A (zh) * | 2021-10-15 | 2024-06-04 | 南通壹宸生物医药科技有限公司 | 一种双特异性结合分子 |
| CN115160408B (zh) * | 2022-06-29 | 2025-04-22 | 辽宁天增祥生物科技有限公司 | 降压肽或中国蛤蜊降压肽提取物及其应用 |
| CN115925981B (zh) * | 2022-08-18 | 2025-05-23 | 河南工业大学 | 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用 |
| EP4626906A1 (en) * | 2022-11-29 | 2025-10-08 | Vacino Biotech Co., Ltd. | Transporter peptides and application thereof |
| TW202434613A (zh) * | 2023-02-17 | 2024-09-01 | 日商肽夢想股份有限公司 | 人類運鐵蛋白受體結合肽 |
| WO2024238304A2 (en) * | 2023-05-12 | 2024-11-21 | University Of Washington | Improved transferrin receptor binding proteins |
| AU2024329222A1 (en) * | 2023-08-18 | 2026-02-12 | Eli Lilly And Company | Engineered transferrin receptor binding peptides as well as methods of making and using the same |
| CN119896743B (zh) * | 2023-10-26 | 2025-09-26 | 华南理工大学 | 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用 |
| WO2025090121A1 (en) * | 2023-10-27 | 2025-05-01 | Yale University | Conjugate and methods of treatment |
| WO2025096245A1 (en) * | 2023-11-02 | 2025-05-08 | The Regents Of The University Of California | Design rules for endosomal escape |
| CN120647772A (zh) * | 2024-03-15 | 2025-09-16 | 迦进生物医药(上海)有限公司 | 特异性结合转铁蛋白受体的多肽及其应用 |
| CN120459270A (zh) * | 2025-05-16 | 2025-08-12 | 中国人民解放军海军军医大学 | OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743893B2 (en) * | 2000-11-30 | 2004-06-01 | The Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| WO2004062602A2 (en) * | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
| US7973019B1 (en) * | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| CA2864126A1 (en) * | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| AU2013266611B2 (en) * | 2012-05-21 | 2016-08-11 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| CN103897033A (zh) * | 2014-03-31 | 2014-07-02 | 中国药科大学 | 转铁蛋白受体TfR特异性结合肽及其应用 |
| WO2016077840A2 (en) * | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS |
| MX391086B (es) * | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| CA3033082A1 (en) | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
-
2019
- 2019-12-13 US US17/312,703 patent/US20220048961A1/en active Pending
- 2019-12-13 AU AU2019398467A patent/AU2019398467A1/en not_active Abandoned
- 2019-12-13 CN CN201980089966.8A patent/CN113329758A/zh active Pending
- 2019-12-13 WO PCT/US2019/066376 patent/WO2020124032A1/en not_active Ceased
- 2019-12-13 CA CA3120466A patent/CA3120466A1/en active Pending
- 2019-12-13 JP JP2021533535A patent/JP7664158B2/ja active Active
- 2019-12-13 EP EP19897452.9A patent/EP3893913B1/en active Active
-
2021
- 2021-06-09 IL IL283839A patent/IL283839A/en unknown
-
2024
- 2024-12-09 JP JP2024214382A patent/JP2025038018A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020124032A5 (https=) | ||
| Thomas et al. | Antibody–drug conjugates for cancer therapy | |
| Nasiri et al. | Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy | |
| Nagayama et al. | Antibody–drug conjugates for the treatment of solid tumors: clinical experience and latest developments | |
| ES2543201T3 (es) | Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138 | |
| Hamidi et al. | New treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance | |
| US20230295285A1 (en) | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent | |
| JP2021107452A (ja) | 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ | |
| JP2018525354A5 (https=) | ||
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| JP2019524713A5 (https=) | ||
| Amani et al. | ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies | |
| CN108602890A (zh) | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 | |
| JP2024542021A (ja) | ペイロードのｉｎ ｖｉｖｏ標的化送達用のテトラジンコンジュゲート | |
| WO2023081809A1 (en) | Trans-cyclooctene-modified bispecific antibodies | |
| JP2022513160A (ja) | 中枢神経系原発リンパ腫の併用治療 | |
| Wu | Enhancement of immunotoxin activity using chemical and biological reagents | |
| TWI812820B (zh) | 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法 | |
| Rossi et al. | Antibody–drug conjugates for the treatment of hematological malignancies: a comprehensive review | |
| JP2022537453A (ja) | セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法 | |
| Chen et al. | Research progress in targeted therapy of hepatocellular carcinoma | |
| Koli et al. | Lung cancer receptors and targeting strategies | |
| Payan et al. | Antibody–Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges | |
| US20250255829A1 (en) | Multifunctional Nanoparticles and Uses in Managing Cancer and Cardiovascular Diseases | |
| US20230257463A1 (en) | In situ thiol-maleimide crosslinked hydrogel for immune checkpoint blockade delivery |